Adjuvant therapy for stage III papillary kidney cancer
Treatments studied
Part of Cancer, Kidney & urinary, Women’s health & pregnancy clinical trials.
This trial tests a tool that helps decide whether people with stage III papillary kidney cancer should get a drug called pembrolizumab (immunotherapy) after surgery. The goal is to see if it lowers the chance of cancer coming back compared to no extra treatment.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have been diagnosed with stage III papillary kidney cancer (papillary renal cell carcinoma).
- You have already had surgery to remove the cancer and the edges of the removed tissue are clear of cancer.
- You have not received any cancer treatment before this surgery.
- You are in generally good health (able to do most daily activities).
- You have not had certain other kidney cancer types (TFE3 or TFEB) or severe health conditions.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This Phase 2 trial tests whether combining bevacizumab, erlotinib, and atezolizumab can shrink or control advanced kidney cancer. It’s aimed at people with certain kidney-cancer subtypes (including HLRCC-related cases or papillary kidney cancer) and who have not had many prior targeted or immune treatments.
This trial tests a combination of three drugs—an immunotherapy (pembrolizumab) and two targeted therapies (belzutifan and lenvatinib)—given before surgery for high-risk kidney cancer. The goal is to see if this combination can shrink the tumor and improve outcomes after surgery.
This trial tests whether the drug pembrolizumab, given after surgery to remove kidney cancer, can help prevent the cancer from coming back. Pembrolizumab helps your immune system fight cancer cells.
This Phase 3 trial studies additional (adjuvant) treatment after kidney cancer surgery, to lower the chance the cancer comes back. It tests immunotherapy drugs (durvalumab and tremelimumab) in people whose scans show no visible remaining cancer after operation.
This trial is testing if adding the targeted therapy tivozanib to the immunotherapy drug pembrolizumab (Keytruda) can help prevent kidney cancer from coming back after all known tumors have been removed by surgery.
This trial tests two drugs, alone or together, given before surgery to shrink kidney cancer tumors. It aims to see which approach works best for patients with intermediate- to high-risk clear cell renal cell carcinoma.
Hear when a new Papillary Renal Cell Carcinoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.